[26 April 2013]
Products Affected - Description
Timentin powder for injection, GlaxoSmithKline
3.1 gram ADD-Vantage vial (NDC 00029-6571-40) - discontinued
3.1 gram vial (NDC 00029-6571-26)
31 gram bulk package (NDC 00029-6579-21)
Reason for the Shortage
- GlaxoSmithKline could not provide a reason for the shortage.
- GlaxoSmithKline discontinued Timentin 3.1 gram ADD-Vantage vials in late-2012.
Timentin powder for injection, Baxter
3.1 gram/100 mL frozen bags (NDC 00029-6571-31)
Estimated Resupply Dates
GlaxoSmithKline has Timentin 3.1 gram vials and 31 gram bulk vials on back order and the company cannot estimate a release date.
April 26, 2013; March 26, 2013; February 13, 2013; January 15, 2013; December 4, 2012; October 12, 2012; June 25, 2012; April 5, 2012; March 7, 2012; February 8, 2012; January 4, 2012; December 7, 2011; November 16, 2011; October 12, 2011; September 14, 2011; August 16, 2011; July 12, 2011; June 23, 2011; June 9, 2011; June 6, 2011, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins